Soluble Mesothelin-Related Peptides (SMRP)

Soluble Mesothelin-Related Peptides (SMRP) are protein fragments shed into the bloodstream by cells that produce mesothelin, including many mesothelioma tumor cells. A blood test measures SMRP levels, which tend to be higher in people with epithelioid or biphasic pleural mesothelioma. SMRP is used as a supportive marker. It can't diagnose mesothelioma on its own, but it can help raise suspicion and track how a known tumor is responding to treatment.

Origin

Mesothelin was identified in the 1990s by Ira Pastan and colleagues at the National Cancer Institute as a cell-surface protein on normal mesothelial cells and overexpressed in mesothelioma. The soluble, circulating form (SMRP) was characterized in the early 2000s by Robinson and colleagues in Australia, and the MESOMARK assay measuring SMRP received FDA clearance in 2007 under the Humanitarian Device Exemption pathway.

Significance in Asbestos Context

For patients with known or suspected asbestos exposure, SMRP is one of the few blood-based tools that can support a mesothelioma workup or monitor treatment response. Elevated SMRP is most useful in epithelioid pleural mesothelioma; it is much less sensitive for sarcomatoid mesothelioma and for peritoneal disease. A normal SMRP does not rule out mesothelioma, and elevated levels can occur in ovarian and pancreatic cancers and in kidney failure, so results must be interpreted alongside imaging and tissue biopsy. In a legal claim, serial SMRP values in your medical records can help document the timing of disease onset and response to therapy, which may be relevant to damages and to causation experts.

Example Sentence

After his pleural plaques were found on a CT scan, the oncologist ordered an SMRP blood test as one piece of the evaluation for possible mesothelioma.

Related Terms

Mesothelioma, Mesothelin, Biomarker, MESOMARK Assay, Pleural Biopsy, Fibulin-3

Notes

• Ask your oncologist whether SMRP testing (MESOMARK) is appropriate for your tumor type. It is most informative in epithelioid pleural mesothelioma and less useful in sarcomatoid or peritoneal disease.
• Do not rely on a single SMRP value; ask for trend data over time, since rising levels during or after treatment can signal progression and falling levels can suggest response.
• Tell your doctor about kidney disease, ovarian cancer history, or other conditions that can elevate SMRP and cause false positives.
• Preserve copies of all SMRP lab reports along with pathology, imaging, and treatment records. These become part of the medical timeline your legal team and experts will rely on.
• SMRP is not a screening test for people with asbestos exposure who have no symptoms; current guidelines do not recommend it for general surveillance.